Trial Profile
Pembrolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC) Patients Expressing PD-L1 Who Have Their Own Patient-derived Xenograft (PDX): Comparative Study of Clinical Response and In-vivo Antitumor Response Using Their Humanized CD34 PDX (Hu-CD34 PDX)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Nov 2022 Planned End Date changed from 30 Jun 2021 to 30 Aug 2023.
- 04 Dec 2020 Planned End Date changed from 29 Feb 2020 to 30 Jun 2021.
- 04 Dec 2020 Status changed from not yet recruiting to recruiting.